Wendy Saffell-Clemmer, leads the Baxter Biopharma Solutions (BPS) development team responsible for the development of final drug product formulation and analytical method development, validation, and transfer for customer products. Wendy has 25 years’ experience in the development and analysis of biopharmaceutical products and has held a variety roles at Baxter including Director of the Global Analytical Center of Excellence, responsible for extractable & leachable, elemental impurity, impurity characterization and microscopy and particle analysis, Lead Scientist and leader of the Baxter Chemistry Community of Practice and Sr. Director for Baxter Pharmaceuticals Business Operations. Wendy volunteers as the chair of the USP BIO 2 Proteins Expert Committee for the 2020-2025 cycle and is a member of the Editorial Advisory Board for the PDA Journal of Pharmaceutical Science and Technology. Wendy has a B.S. in Chemistry from the University of Virginia and an M.S. in Physical Chemistry from Northwestern University.